Press Release Details
Twist Bioscience Announces Proposed Public Offering of Common Stock
Twist intends to use the net proceeds of the offering, along with its
existing cash, cash equivalents and short-term investments to improve
and update its platform and core technologies by investing in equipment,
expanding its NGS research and development capabilities, investing in
production software, consolidating into new operation facilities and
increasing its production capacity. It also intends to use the proceeds
of the offering to expand its commercial operations including marketing,
NGS sales and technical services in
A registration statement relating to these securities has been filed
with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements
other than statements of historical facts contained herein are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995, including, but
not limited to, market conditions and the completion of the public
offering on the anticipated terms or at all. Such forward-looking
statements involve known and unknown risks, uncertainties, and other
important factors that may cause Twist Bioscience’s actual results,
performance, or achievements to be materially different from any future
results, performance, or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include, among
others, the risks and uncertainties of the ability to attract new
customers and retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive competition
in synthetic biology could make the products Twist Bioscience is
developing obsolete or non-competitive; uncertainties of the retention
of a significant customer; risks of third party claims alleging
infringement of patents and proprietary rights or seeking to invalidate
Twist Bioscience’s patents or proprietary rights; and the risk that
Twist Bioscience’s proprietary rights may be insufficient to protect its
technologies. For a further description of the risks and uncertainties
that could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk factors
set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with
the
View source version on businesswire.com: https://www.businesswire.com/news/home/20190506005721/en/
Source:
Twist Investor Contact:
Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com
Twist
Media Contact:
Angela Bitting
925-202-6211
media@twistbioscience.com